Figures & data
Table 1 Drug combinations used for the treatment of patients with COPD
Figure 1 The proposed algorithm for the management of patients with stable COPD.
Notes: *Evaluation of symptoms is based on the CAT questionnaire, if there was more than one clinical exacerbation or one clinical event leading to hospitalization during one year of follow-up. **Pathophysiological endotyping: 1) eosinophilic endotype with peripheral blood eosinophilia or sputum eosinophilia >3%; 2) neutrophilic endotype with peripheral blood neutrophilia of >60% or with green sputum; or 3) pauci-granulocytic endotype.
Abbreviations: CAT, COPD assessment test; FEV1, forced expiratory volume in one second; GPs, general physicians; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting beta-agonist; SAMA, short-acting muscarinic antagonist.
Abbreviations: CAT, COPD assessment test; FEV1, forced expiratory volume in one second; GPs, general physicians; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting beta-agonist; SAMA, short-acting muscarinic antagonist.
![Figure 1 The proposed algorithm for the management of patients with stable COPD.](/cms/asset/e439ff47-d831-4122-a74e-9cd84ef1c07a/dcop_a_125594_f0001_c.jpg)